Royalty Pharma Price to Free Cash Flow Ratio 2019-2024 | RPRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Royalty Pharma average price to free cash flow ratio for 2024 was 6.65, a 13.48% increase from 2023.
Royalty Pharma average price to free cash flow ratio for 2023 was 5.86, a 20.16% increase from 2022.
Royalty Pharma average price to free cash flow ratio for 2022 was 7.34, a 263.37% decline from 2021.

Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Royalty Pharma average price to free cash flow ratio for 2024 was 6.65, a 13.48% increase from 2023.
Royalty Pharma average price to free cash flow ratio for 2023 was 5.86, a 20.16% increase from 2022.
Royalty Pharma average price to free cash flow ratio for 2022 was 7.34, a 263.37% decline from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
American Express (AXP)	$217.7B
Blackstone (BX)	$120.5B
Moody's (MCO)	$93.5B
Coinbase Global (COIN)	$64.8B
Brookfield Asset Management (BAM)	$26.9B
Synchrony Financial (SYF)	$25.5B
Orix Corp Ads (IX)	$24.6B
SoFi Technologies (SOFI)	$17.6B
Equitable Holdings (EQH)	$17.4B
Jefferies Financial Group (JEF)	$14.3B
BB Seguridade Participacoes SA (BBSEY)	$14B
Houlihan Lokey (HLI)	$12.8B
Globe Life (GL)	$10.4B
Daiwa Securities Group (DSEEY)	$9.8B
Freedom Holding (FRHC)	$9.5B
Brookfield Wealth Solutions (BNT)	$8.8B
XP (XP)	$8.1B
SouthState (SSB)	$7.8B
Upstart Holdings (UPST)	$7.8B
StepStone Group (STEP)	$7.3B
Rithm Capital (RITM)	$6.2B
Blue Owl Capital (OBDC)	$6.1B
Lazard (LAZ)	$6.1B
Virtu Financial (VIRT)	$5.9B
Euronet Worldwide (EEFT)	$4.8B
PJT Partners (PJT)	$4.2B
AXOS FINANCIAL, INC (AX)	$4B
StoneX Group (SNEX)	$4B
Intercorp Financial Services (IFS)	$3.7B
Abrdn (SLFPY)	$3.6B